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Abstract
Two of the more common potential complications after arthroplasty are venous thromboembolism (VTE), which includes deep
vein thrombosis (DVT) and pulmonary embolus (PE), and excess bleeding. Appropriate chemoprophylaxis choices are essential to
prevent some of these adverse events and from exacerbating others. Risk stratification to prescribe safe and effective medications
in the prevention of postoperative VTE has shown benefit in this regard. The Department of Orthopaedic Surgery at Syosset
Hospital/Northwell Health, which performs over 1200 arthroplasties annually, has validated and is using the 2013 version of the
Caprini Risk Assessment Model (RAM) to stratify each patient for risk of postoperative VTE. This tool results in a culling of
information, past and present, personal and familial, that provides a truly thorough evaluation of the patient’s risk for postoperative VTE. The Caprini score then guides the medication choices for thromboprophylaxis. The Caprini score is only valuable
if the data is properly collected, and we have learned numerous lessons after applying it for 18 months. Risk stratification requires
practice and experience to achieve expertise in perioperative patient evaluation. Having access to pertinent patient information,
while gaining proficiency in completing the Caprini RAM, is vital to its efficacy. Ongoing, real time analyses of patient outcomes,
with subsequent change in process, is key to improving patient care.
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Historically, total joint arthroplasty (TJA) was a procedure
requiring 3 to 5 days of medical and surgical stabilization in
the hospital followed by extended postoperative rehabilitation
at a subacute facility. Over the last few years, it has transitioned
to an enhanced recovery after surgery (ERAS) process, with
discharge to the home occurring within 1 to 2 days. This
requires a collaborative team to optimize postoperative recovery and minimize complications. Two of the more common
potential complications after arthroplasty are venous thromboembolism (VTE), which includes deep vein thrombosis
(DVT) and pulmonary embolus (PE), and excess bleeding.
Bleeding events include wound bleeding, hematoma, delayed
wound healing, dehiscence, infection, compromised functional
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Table 1. Venous Thromboembolism Outcomes.
Age/
gender Procedure
57 F

Risk group

VTE prophylaxis

VTE/POD

COMMENTS
Patient primarily in bed after side 1. Preop Doppler
performed Friday before side 2 (Monday)
Acute on chronic DVT. Caprini 12 for side 1

HIGH risk

Enox 30mg q12h after side 1; Apix
2.5mg q12h after side 2
Enox 30mg q12h after side 1; Apix
2.5mg q12h after side 2
Enox 30mg q12h after side 1; Apix
2.5mg q12h after side 2
Apix 2.5mg q12h

85 F

Staged
TKA
Staged
TKA
Staged
TKA
TKA

79 F
60 M
62 F

THA
THA
THA

HIGH risk
LOW risk
LOW risk

Apix 2.5mg q12h
ASA 81mg q12h
ASA 81mg q12h

Bilat PE POD1
after side 2
DVT POD2
after side 1
PE POD2 after
side 2
DVT POD3
Bilat PE POD6
DVT POD7
DVT POD6
PE POD54

63 F

THA

LOW risk

ASA 81mg q12h

PE POD22

59 M
71 M

HIGH risk
HIGH risk
HIGH risk

History DVT; Caprini 11 for side 1
Medically unstable; unable to ambulate until POD3
Patient readmitted with fever and DVT
Preop hip fracture. Patient should have been high risk.
Pt instructed to separate ASA and Meloxicam but took
them together
ASA and Celecoxib administered together at SAR

VTE: venous thromboembolism; POD: postoperative day; F: female; M: male; TKA: total knee arthroplasty; THA: total hip arthroplasty;
Enox: enoxaparin; Apix: apixaban; ASA: aspirin; PE: pulmonary embolus; DVT: deep vein thrombosis; bilat: bilateral; preop: preoperative;
AKI: acute kidney injury; SAR: subacute rehabilitation center.

outcome, and increased need for allogeneic blood transfusion.1
Appropriate chemoprophylaxis choices are essential to prevent
some of these adverse events and from exacerbating others.
Risk stratification to prescribe safe and effective medications
in the prevention of postoperative VTE has shown benefit in
this regard.2-4 Horner et al, performed a recent study to identify
optimal chemoprophylaxis for patients requiring lower limb
immobilization after injury. The authors described an urgent
need for research to improve the evidence base with external
validation studies looking for customizable tools to guide
thromboprophylaxis.5
Without prophylaxis the reported rates of VTE were 40-60%
after total hip arthroplasty (THA) and 40-85% after total knee
arthroplasty (TKA).6 Incidence of VTE has been profoundly
reduced by a wealth of research that have led to effective
national guidelines.1,7 A recent publication by Warren et al,
in reviewing VTE data from 2008 to 2016, found the 30-day
incidence of VTE to be 0.6% for THA and 1.4% for TKA.8
However, we are always driven to “chase zero” in an attempt to
minimize the burden of these complications which not only
increase morbidity and mortality, but are costly in terms of
healthcare dollars.9-11
The Department of Orthopaedic Surgery at Syosset Hospital/Northwell Health, which performs over 1200 arthroplasties
annually, has validated12 and is using the 2013 version of the
Caprini Risk Assessment Model (RAM)13 to stratify each
patient for risk of postoperative VTE. The Caprini score then
guides the medication choices for thromboprophylaxis. All
surgeons follow one protocol. THA patients scored as highrisk receive apixaban 2.5 mg twice daily for 35 days. TKA
patients who score as high-risk receive apixaban 2.5 mg twice
daily for 12 days followed by aspirin (ASA) enteric coated
(EC) 81 mg twice daily for an additional 4 weeks. All patients
classified as low-risk, after THA or TKA, receive ASA EC 81
mg twice daily for 6 weeks. Over the past 5 years, we have

reduced the ASA dose from 325 mg twice daily, to 162 mg
twice daily, and finally to 81 mg twice daily. Risk assessment
has allowed us to confidently reduce the dose of ASA in lowrisk patients to 81 mg twice daily based on published
outcomes.14-16 Patients report improved gastrointestinal tolerability with ASA EC 81 mg twice daily compared to the higher
doses previously prescribed.
The Caprini score is only valuable if the data is properly
collected, and we have learned numerous lessons after applying it for 18 months. First and foremost, a detailed personal
and family history of thrombotic events in the patient or any
relative is vital to this end.17 Patients at our institution complete a patient-friendly version of the Caprini RAM in presurgical testing (PST), and are then further questioned if they
indicate personal or family history of any known risk factors.18 Simultaneously, well-trained clinicians complete the
Caprini RAM, utilizing information from the history and
physical performed in PST as well as the medical clearances
required prior to surgery. BMI is accounted for only after the
patient is weighed in the preoperative area on the day of
surgery. The result is a culling of information, past and present, personal and familial, that provides a truly thorough
evaluation of the patient’s risk for postoperative VTE. This
generates a Caprini score which allows us to assign the
patient to low-risk (Caprini score < 10) or high-risk (Caprini
score  10).12 In 2019, 53% of our patients were low-risk
and 47% of patients were high-risk.
Every member of the team, including surgeons, nurses, hospitalists, orthopaedic physician assistants, physical and occupational therapists, has been educated concerning the risk
factors that could alter a patient’s score. Specifically, during
hospitalization, this includes blood transfusion,19,20 inability to
ambulate at least 30 feet continuously,21 and placement of a
brace that impedes contraction of the calf muscles during
ambulation.5 The team is fully engaged in this process and each
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health care professional has been instrumental in identifying
and communicating added risk factors to ensure the score is
adjusted appropriately. Risk assessment continues from hospitalization to the home, by partnering with the surgeons’ offices,
since any additional risk factor(s) can change the patient’s
score and potentially alter the thromboprophylactic regimen
during the 6 weeks after surgery.
We maintain a prospective joint arthroplasty registry for all
surgical candidates. In addition, all patients are called 60 days
after surgery to capture outcomes, both negative and positive.
For the calendar year 2019, we identified 8 postoperative VTEs
(Table 1). Since implementation of risk assessment with the
2013 Caprini RAM in mid-2018, our skill in assessing patients
to prevent postoperative thrombosis has improved dramatically. We credit this to the utility and validity of the Caprini
tool.
Three of the 8 postoperative VTE occurred in staged, bilateral patients. These patients underwent a total knee arthroplasty
on the day of admission, remained in the hospital, and 5 days
later underwent a contralateral second total knee arthroplasty.
All patients received enoxaparin 30 mg subcutaneously q12 h
beginning the morning of postoperative day (POD)1 with discontinuation after the morning dose on the day prior to the
second surgery. All patients received a doppler of the lower
extremities to rule out DVT prior to the second surgery. Of the
3 patients with postoperative VTE, 1 was not ambulating sufficiently after the first surgery, and bilateral PEs were identified
on POD1 after side 2. This led immediately to a protocol revision; patients must ambulate at least 150 feet and be cleared by
physical therapy to proceed with side 2. If this is not the case,
the second surgery is canceled and rescheduled for a later date.
The other 2 patients both had a personal history of DVT and
developed a VTE (1 DVT, 1 PE) on POD2 after the second
surgery. Again, the joint arthroplasty protocol was revised to
contraindicate staged procedures in patients with a Caprini
score of 10 or greater for the first surgery. If the patient requires
bilateral arthroplasties, the surgeries are scheduled at least
3 months apart.
The remaining 5 patients were unilateral surgeries. Two
were risk stratified to high-risk and 3 to low-risk. Both highrisk patients were older females (79 and 85 years of age). One
was readmitted on POD6 with a fever and found to have a
DVT. The other patient developed severe postoperative acute
kidney injury and was bedridden for 3 days until she was
medically stable to ambulate. Both patients received apixaban
combined with mechanical prophylaxis (intermittent pneumatic compression) during hospitalization for prevention
of VTE.
Of the low-risk patients, one was identified as having been
diagnosed with a preoperative fracture that was not communicated to the team and was not captured in the Caprini score.
This would have ranked the patient as high-risk rather than
low-risk, which would have changed the thromboprophylaxis
regimen. The surgeons were alerted that this was important
historical information for risk stratification, and this further
advanced our skill in stratifying patients.
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Finally, 2 of the low-risk patients took the ASA prescribed
for VTE prophylaxis and the NSAID, used for multimodal pain
management (celecoxib 200 mg twice daily, meloxicam 15 mg
once daily), together. We did not identify this drug interaction,
whereby the NSAID may cause competitive inhibition of ASA
at the platelet receptor site, until we reduced the dose to 81 mg
twice daily.22 Also referred to as a potential cause of “aspirin
resistance,”23 this interaction had been reported with traditional
NSAIDs but not with cyclooxygenase (COX)-2 inhibitors.24-27
A robust literature search revealed a drug interaction between
ASA and higher-dose NSAIDs that possess greater cyclooxygenase (COX)-2 activity.28-30 This interaction, however, was
not found to occur when studying ASA in doses greater than
100 mg.26,31 Thus, ASA is now administered at least 2 hours
prior to celecoxib or meloxicam in the hospital. Additionally,
our patients are fully educated about this drug interaction. All
patients are provided with a personalized medication calendar
upon hospital discharge to assist with medication compliance
as well as safe timing of drug administration. To date, we have
not had any further VTE events in this low-risk group.
The authors believe that appropriate thromboprophylaxis
following total joint arthroplasty is optimally managed through
risk stratification. It is not best addressed with a one-size-fitsall approach. Validation and acceptance of a risk stratification
tool in the arthroplasty population is still controversial within
the orthopaedic community. The goal is to create a process that
is accurate, reproducible, and time efficient. Multiple attempts
at creating a risk stratification tool have been published in the
orthopedic literature. Mantilla et al, sought to create a targeted
approach to thromboprophylaxis following TJA. Although they
identified multiple factors associated with increased incidence
of VTE, the quality of the data was solely dependent on the
accuracy and completeness of medical records and information
available through an institutional total joint registry.32 Parvizi
et al, also recognizing the advantages of a strategy to individualize anticoagulation choices based on patient stratification,
identified several risk factors for postoperative PE.33 The study
identified comorbidities using ICD-9 codes, which are not
always accurate, and only recorded PE if it was diagnosed at
their own institution. In a subsequent publication, Parvizi et al,
used the Nationwide Inpatient Sample (NIS) database, extracting diagnoses with ICD-9 codes to create a VTE estimator
application; endpoints included only in-hospital VTE, and the
study did not delineate the type of chemoprophylaxis used.34
Bohl et al, developed a risk stratification system to identify risk
of PE following TJA using the American College of Surgeons
National Surgical Quality Improvement Program (ACSNSQIP), a surgical registry, to capture patient clinical data.35
The study included only 30-day followup, contained no history
of VTE or thrombophilia (information not captured by the
registry), and risk stratification was determined without knowledge of the chemoprophylaxis administered. The authors noted
that their stratification system was “optimal for use in patients
without severe risk factors” in a “standard-risk” population.35
Bateman et al, tested the Caprini RAM in 363 arthroplasty
patients and determined it was not clinically useful; the authors
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Table 2. Performance Improvement Initiatives.
VTE occurrence

Performance improvement

Patient not ambulating sufficiently after side 1 of
Patient must be ambulating 150 feet and cleared by physical therapy before
staged bilateral procedures
surgeon may proceed with side 2
Preoperative finding of hip fracture prior to scheduled Team educated that fracture increases risk of postop VTE and Caprini score
THA
and must be communicated
Low risk patients taking ASA EC 81mg q12h
Patients given explicit instructions to take ASA 81mg at least 2 hours before
concurrently with NSAID
NSAID to maintain ASA efficacy
VTE: venous thromboembolism; THA: total hip arthroplasty; ASA EC: aspirin enteric-coated; NSAID: nonsteroidal anti-inflammatory drug; postop: postoperative.

reported that the tool was completed accurately in only 7% of
patients studied.36 Kulshrestha and Kumar performed a randomized study looking at routine anticoagulation versus risk
screening using their own risk assessment tool which was very
similar to the Caprini RAM. They assigned a score equivalent
to 7 as their cut-off for high risk. Although they found no
difference in incidence of VTE, they identified a statistically
significant increase in wound complications in the routine
anticoagulation group (8.4% versus 4.4%; RR 1.9 [1.1 to
3.2]).37 Finally, Warren et al, also used the NSQIP database
to identify annual trends of VTE and mortality between 2008
and 2016 following joint arthroplasty; they specifically
reported that although their analysis included several factors
identified by the Caprini scoring system, it was also deficient in
capturing other well-known variables such as patient history
and/or family history of VTE, and genetic coagulopathies.8
Choosing appropriate chemoprophylaxis for VTE is a balance between efficacy and safety in order to optimize patient
outcomes. It requires practice and experience to achieve expertise in perioperative patient evaluation. We credit the implementation of the 2013 Caprini RAM for these lessons learned,
which have resulted in revisions to our protocols. Over the past
18 months, after implementing this process of risk stratification
in prescribing VTE prophylaxis after TJA, every incidence of
DVT or PE has been analyzed, and has led to protocol revisions
with subsequent improvement in outcomes. If a patient is
scheduled for staged, bilateral surgeries they must now be
ambulating sufficiently and cleared by physical therapy
before the second surgery is performed. Additionally, any
patient who is deemed high-risk for VTE for the first surgery
(each surgery adds 5 points to the Caprini score) will not be
considered a candidate for staged procedures. Surgeons have
been educated that if a patient who scheduled for elective
THA is found to have a fracture prior to surgery, the team
should be informed so the patient can be more accurately risk
stratified. Finally, a significant drug interaction between ASA
EC 81 mg and high-dose celecoxib or meloxicam was identified upon dose reduction of ASA EC from 162 mg to 81 mg.
Comprehensive patient education in describing the importance of taking ASA at least 2 hours prior to the NSAID to
maintain ASA efficacy is performed prior to discharge; no
further incidence of VTE in patients taking these 2 medications concurrently has been identified since intensifying this
educational component (Table 2).

The discussion of lessons learned must also address the
importance of critical thinking and clinical judgment. The
Caprini RAM, like any other risk stratification tool, provides
guidance for prescribers. If it is determined that a patient would
receive greater benefit from one regimen compared to another,
this should ultimately drive practice. An example of this is a
patient who had an undiagnosed patent foramen ovale (PFO)
and subsequently developed a stroke with a paradoxical VTE
after arthroplasty. Since then, any patient with a diagnosed PFO
is considered high-risk and receives oral anticoagulation postoperatively regardless of their assessed score.
Individual risk assessment for thrombosis related complications has never been more important than during the Coronavirus pandemic. The Caprini RAM is a dynamic tool, requiring
ongoing evaluation of the patient during the postoperative
period.12 Patients with a previous history of Coronavirus infection should not be considered for surgical procedures for at
least 3 months unless the surgery is considered urgent. Patients
with active Coronavirus disease who require urgent surgery
have a 50% chance of developing a postoperative thrombotic
event as well as mortality rates of 25% or greater.38 Preliminary
data appear to suggest adding 2 points to the Caprini score for
asymptomatic Coronavirus positive patients, 3 points if symptoms are present, and 5 points in Coronavirus positive patients
with elevated D-dimer.39
On March 13, 2020, elective orthopaedic surgery resumed at
our institution. It was necessary to implement new perioperative processes to ensure optimal patient outcomes. All patients
must have a negative polymerase chain reaction (PCR) nasal
swab within 48 hours of surgery. Additionally, the preoperative history now includes a detailed patient assessment for
confirmed Coronavirus, either by nasal swab or antibody testing, or symptoms highly suspicious of the viral disease within
the prior 6 months. Any patient with a known case of Coronavirus disease receive an additional 2 points on the Caprini
RAM.39 Patients hospitalized for severe COVID-19 disease, or
those diagnosed with COVID pneumonia, require further diagnostic testing prior to surgery, including a D-dimer. COVID-19
has highlighted the necessity for any risk stratification tool to
evolve in order to account for unforeseen events.
Having access to pertinent patient information, while gaining proficiency in completing the Caprini RAM, are both vital
to its efficacy. Ongoing, real time analyses of patient outcomes,
with subsequent change in process, is key to improving patient
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care. Every new initiative has its own learning curve, but the
knowledge acquired by implementing risk stratification for
venous thromboprophylaxis has enriched our attention to detail
in the quest for excellence following total joint arthroplasty.
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